Hikma Pharmaceuticals Plc FTC preliminary approval for Custopharm (6696I)
April 20 2022 - 2:10AM
UK Regulatory
TIDMHIK
RNS Number : 6696I
Hikma Pharmaceuticals Plc
20 April 2022
London, 20 April 2022 - Hikma Pharmaceuticals PLC (Hikma,
Group), the multinational pharmaceutical group, today confirms it
has received preliminary approval from the US Federal Trade
Commission (FTC) and will now work towards closing its acquisition
of Custopharm Inc. from Water Street Healthcare Partners, as
previously announced on 27 September 2021. The parties have now
obtained all regulatory approvals required to close the
transaction. Hikma will make a further announcement upon the close
of the transaction.
- ENDS -
Enquiries:
Hikma (Investors):
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970
Investor Relations Analyst 709912
Teneo (Press):
+44 (0)7703 330 269/ +44 (0)7464
982426
Charles Armitstead/Camilla Cunningham
US Media
Steven Weiss/David Belian +1 732 788 8279/ +1 848 254 4875
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAELNFDAAEAA
(END) Dow Jones Newswires
April 20, 2022 02:10 ET (06:10 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024